Platelet rich fibrin: A novel treatment for trophic ulcer in Hansen's disease

Dorjay, Konchok; Tandon, Sidharth; Singh, Ajeet; Sharma, Satish C.; Sardana, Kabir

doi:10.1177/00494755211069440

Trop Doct

2022

DOI: 10.1177/00494755211069440

|View full text |Cite

Platelet rich fibrin: A novel treatment for trophic ulcer in Hansen's disease

Konchok Dorjay

Sidharth Tandon

Ajeet Singh

et al.

Abstract: Patients with Hansen's disease are liable to develop non-healing trophic ulcers. The aim of this study was to determine the efficacy of autologous platelet rich fibrin (PRF) applied at weekly intervals in the management of trophic ulcers. The mean age of the patients, duration and size of ulcer were 44.3 years, 7.4 months and 6.25cm2 respectively. After the third sessions of weekly dressing, there was a significant reduction in the ulcer area (p value = 0.015). All ulcers healed by a maximum of six weeks. No… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 7 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Exploring the antimicrobial potential of Leukocyte‐ and Platelet‐Rich Fibrin – an in vitro study

Melo‐Ferraz,

Miller,

Criado

et al. 2024

APMIS

View full text Add to dashboard Cite

This study investigates the antimicrobial properties of leukocyte‐ and platelet‐rich fibrin (L‐PRF) against Enterococcus faecalis (ATCC 29212), Pseudomonas aeruginosa (ATCC 27853), and Candida albicans (ATCC 90028). Infections can hinder wound healing posing challenges. L‐PRF's potential for regeneration and antimicrobial action has been studied. Considering the increasing concern about antibiotic resistance, assessing the antimicrobial properties of L‐PRF provides valuable insights into its potential as a therapeutic agent in postoperative infections. Twenty volunteers were enrolled in the study, following ethical guidelines, and obtaining informed consent. Blood samples were collected and L‐PRF was prepared. Microbial suspensions were prepared, and susceptibility testing was performed using the Kirby‐Bauer agar diffusion method. The study revealed significant heterogeneity in the susceptibility to L‐PRF. All L‐PRF membrane samples exhibited antimicrobial activity against P. aeruginosa, with inhibition zones of 13 mm ± 3.85 SD. Enterococcus faecalis displayed inhibition diameter of 7.25 mm ± 5.15 SD. Candida albicans susceptibility to L‐PRF varied among samples, with both inhibitory and non‐inhibitory results. Results showed varying degrees of antimicrobial activity, particularly against P. aeruginosa, and highlight the complexity of the L‐PRF‐microorganism interaction. Further investigations are needed to elucidate the clinical implications and optimize the use of L‐PRF.

show abstract

Exploring the antimicrobial potential of Leukocyte‐ and Platelet‐Rich Fibrin – an in vitro study

Melo‐Ferraz,

Miller,

Criado

et al. 2024

APMIS

View full text Add to dashboard Cite

show abstract

L‐PRF in extra‐oral wound care

Pinto,

Yu,

Koirala

et al. 2024

Periodontology 2000

View full text Add to dashboard Cite

Leukocyte‐ and platelet‐rich fibrin (L‐PRF), a by‐product of centrifuged autologous whole blood, contains high concentrations of platelets, leukocytes, and fibrin (the latter spontaneously creating a strong 3‐D network (a membrane)). L‐PRF membranes possess several characteristics essential in wound healing, including a barrier function, an antibacterial and analgesic activity, and the release of growth factors enhancing tissue regeneration and neo‐vasculogenesis. This review investigated the role of L‐PRF in treating non‐responding chronic wounds such as diabetic foot, venous leg ulcers, pressure ulcers, complex wounds, leprosy ulcers (Hansen's Disease), and other demanding wounds. Chronic wounds affect millions worldwide, negatively impacting their quality of life, productivity, and life expectancy while incurring high treatment costs for themselves and private and public health systems. L‐PRF has demonstrated clear adjunctive advantages in treating chronic skin wounds, shortening the time to complete wound closure, and improving patient‐reported outcome measures (including reducing pain and minimizing the need for analgesics). Also, in other demanding wounds, L‐PRF facilitates healing. To help clinicians, this article also proposes recommendations for the use of L‐PRF in the treatment of extra‐oral wounds.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Platelet rich fibrin: A novel treatment for trophic ulcer in Hansen's disease

Cited by 2 publications

References 7 publications

Exploring the antimicrobial potential of Leukocyte‐ and Platelet‐Rich Fibrin – an in vitro study

Exploring the antimicrobial potential of Leukocyte‐ and Platelet‐Rich Fibrin – an in vitro study

L‐PRF in extra‐oral wound care

Contact Info

Product

Resources

About